Travel vaccines increase sales by 52%Vax-Befor-Travel

With international travel, post-pandemic is increasingly increasing, including the sales of travel vaccine.

For example, the Bavarian Nordic air conditioning in Denmark announced its preliminary financial results and business progress for the first three months of 2025, including the increase in travel health income by 52% to DKK 680 million compared to the first quarter of 2024.

From May 9, 2025, the increase is primarily due to an increased demand for rabies and ticket encephalitis vaccines.

In addition, the Bavarian Nordic confirmed positive knowledge for its MPOX and Chikungunya vaccines.

Paul Chaplin, President and Chief Executive Officer of the Bavarian Nordic, said in a press release: “We had a very strong first quarter for our travel health business, which shows growth of 52% a year compared to the year.”

“After its approval in February 2025, we also recorded our first US vaccine in the US vaccine in the United States. Our step -by -case starting plan for the vaccine has progressed as planned. The first European markets will be online in the next few months. We will also continue our efforts to expand the regulatory systems to other areas.”

“Chikungunya is an increasing threat to public health worldwide, and we are proud to have entered our first partnership to improve access to the vaccine for countries with low and medium -sized incomes.”

With regard to the public willingness in March, the Food and Drug Administration (FDA), which was dried by Jynneos® vaccine (MVA-BN®, IMVAMUNE®), was approved in March to prevent small and MPOX diseases in adults.

From May 2025, Kladen 1 and 2 of the MPOX will remain global health risks, especially in Africa.

The approval supports the ongoing contract with the US government to store the vaccine. In May, the US government practiced additional options worth $ 143.6 million in the context of the existing agreement for the supply of a freezer-dried formulation of the jynneos sackpox vaccine with planned delivery in 2026.

Overall, the company’s turnover rose by 62% in the first three months to DKK 1,347 million.